<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-title>Journal of Translational Medicine</journal-title><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15500699</article-id><article-id pub-id-type="pmc">PMC528853</article-id><article-id pub-id-type="publisher-id">1479-5876-2-36</article-id><article-id pub-id-type="doi">10.1186/1479-5876-2-36</article-id><article-categories><subj-group subj-group-type="heading"><subject>Commentary</subject></subj-group></article-categories><title-group><article-title>Granzyme B; the chalk-mark of a cytotoxic lymphocyte</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Waterhouse</surname><given-names>Nigel J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>nigel.waterhouse@petermac.org</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Sedelies</surname><given-names>Karin A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>karin.sedelies@petermac.org</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Clarke</surname><given-names>Chris JP</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>chris.clarke@petermac.org</email></contrib></contrib-group><aff id="I1"><label>1</label>Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, 8006, Australia</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>25</day><month>10</month><year>2004</year></pub-date><volume>2</volume><fpage>36</fpage><lpage>36</lpage><ext-link ext-link-type="uri" xlink:href="http://www.translational-medicine.com/content/2/1/36"/><history><date date-type="received"><day>27</day><month>9</month><year>2004</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Waterhouse et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Waterhouse et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Waterhouse
               J
               Nigel
               
               nigel.waterhouse@petermac.org
            </dc:author><dc:title>
            Granzyme B; the chalk-mark of a cytotoxic lymphocyte
         </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>Journal of Translational Medicine 2(1): 36-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1479-5876(2004)2:1&#x0003c;36&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1479-5876</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>During cytotoxic lymphocyte (CL) mediated killing of target cells, granzyme B is released from the CL into the immune synapse. Recent studies have found that ELISPOT-detection of granzyme B correlated well with conventional assays for CL mediated killing. In this way, the released granzyme B can be used to mark the spot where a target cell was murdered. We discuss the benefits and potential limitations of using this assay to measure CL mediated killing of target cells.</p></abstract></article-meta></front><body><sec><title>Introduction</title><p>Cytotoxic Lymphocytes (CLs) eliminate virally infected cells or tumour cells either by activating death receptors or by delivering cytotoxic granule proteins (granule exocytosis) to the target cell [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. The ability of a virus or a tumour cell to evade detection or survive an attack by CLs is likely to result in a more aggressive disease. The ability to measure specific killing of target cells by CLs is therefore of great interest to clinicians and researchers alike. Any assay for CL-induced death involves mixed cultures of target and effector cells and must include some means of distinguishing between the two. The current approach is to measure the release of a label, such as <sup>51</sup>Cr or, more recently calcein-AM [<xref ref-type="bibr" rid="B3">3</xref>], that has been preloaded into the target cells. Radioactivity limits the utility of <sup>51</sup>Cr and, although this type of assay is presumed to measure rupture of the plasma membrane (cell lysis), it is not formally known what is being measured.</p></sec><sec><title>Discussion</title><p>Various alternative assays have been developed to assay CL-induced killing of target cells [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B10">10</xref>], however <sup>51</sup>Cr remains the gold standard. Recently, Shafer-Weaver <italic>et al </italic>and others have utilized an interesting strategy aimed at measuring the functions of effector cells rather than death of the target cell [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. During granule-mediated killing, granule enzymes (granzymes) are transferred to the target cell [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. In the target cell granzyme B, can initiate target cell death by apoptosis [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Shafer-Weaver <italic>et al</italic>., [<xref ref-type="bibr" rid="B11">11</xref>] demonstrated that detection of granzyme B by ELISPOT correlated well with <sup>51</sup>Cr release during antigen specific target cell death induced by cytotoxic T-lymphocytes and now report utility of this assay for measuring MHC non-restricted killing by natural killer cells [<xref ref-type="bibr" rid="B15">15</xref>]. Following incubation of CL with their targets, <italic>Shafer-Weaver et al</italic>., measured granzyme B by ELISPOT and found that the number of SPOTS correlated well with results obtained by the <sup>51</sup>Cr release assay. Unlike the <sup>51</sup>Cr release assay, this ELISPOT assay measures a specific and well-characterized event that occurs following target recognition. Assessing granzyme B by ELISPOT appears superior to other markers, such as IFN&#x003b3;, because it assays a molecule that directly participates in CL mediated killing. Furthermore, the assay is non-radioactive and under the experimental parameters reported, it appears possible to detect cytolytic activity using fewer cells than are required for <sup>51</sup>Cr release.</p><p>This assay appears to provide an effective alternative method for assessing CL-mediated cell death, however, users should be aware of possible limitations. The assay measures granzyme B release, not cell death. Frequently, the two will be closely correlated, but under certain circumstances using granzyme B release as a marker could lead either to an under or over estimate of target cell death. For example, perforin-deficient CLs are unable to kill targets [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>], yet they may release granzyme B in the same way as wild type cells -leading to a false positive result. Alternatively, cells lacking, or expressing small amounts of granzyme B may retain the ability to kill targets by means of other granule components or through death receptor mediated pathways leading to an underestimate of cytotoxic activity [<xref ref-type="bibr" rid="B18">18</xref>]. In addition, a CL may degranulate normally, but certain targets may be inherently resistant to their effects [<xref ref-type="bibr" rid="B19">19</xref>]. Thus, to be certain that degranulation is inducing target cell death, chromium release assays should be performed alongside the granzyme B ELISPOT.</p><p>The limits of detection of this assay are not clear. It is not known whether the granzyme B released at a single death-inducing synapse are sufficient to produce a spot or whether a CL must degranulate several times, possibly killing multiple targets, to facilitate detection. Even if one spot reflects degranulation by one CL and is directly equivalent to one target cell death, it remains possible that CLs expressing granzyme B below the level of detection by ELISPOT may express sufficient granzyme B to kill their targets. These are difficult issues to address, but the correlation between <sup>51</sup>Cr and granzyme B ELISPOT shown under the conditions used by <italic>Shafer-Weaver et al </italic>[<xref ref-type="bibr" rid="B15">15</xref>] suggests that the levels of detection of the assay are likely to be broadly equivalent to those required for cell death. It is however too difficult to directly compare these two assays. For example, 316 spots were detected in an assay using 50,000 target cells and 10,000 effectors (Table 1). This is equivalent to 0.6 +/- 0.1 % (as the number of spots must be related to the number of targets for comparison with <sup>51</sup>Cr). Increasing the effectors generated too many spots to count. Therefore an experiment optimised for <sup>51</sup>Cr assay, (0&#x02013;70% release as reported in Table 1), will only have a dynamic range of between 0 and 0.6% using the ELISPOT assay. In contrast, an assay optimized for ELISPOT is likely to be off scale in a <sup>51</sup>Cr release assay. These data suggest that a small amount of killing (e.g in a sample with low level killing) may easily generate a positive result by ELISPOT. It is therefore likely that stringent titration of both effectors and targets over a narrow range will be essential.</p></sec><sec><title>Conclusion</title><p>The granzyme B-ELISPOT introduces a new assay for measuring CL mediated toxicity that will have a widespread utility in experimental systems where granzyme B is present in the effector cell and the target is susceptible to CL mediated killing. However, no assay used in isolation can be the answer to everyone's prayers and the granzyme B ELISPOT, like all others, has limitations. There is no doubt that this assay measures triggering of degranulation, but it does not directly address the question of cell death. Therefore it is likely that the greatest utility of this assay will be found by using it in combination with other existing measures of cytotoxic activity. It may also be extremely valuable as a quick reference to determine whether killing can occur in an assay with defined targets and effectors.</p></sec><sec><title>Abbreviations</title><p>CL, cytotoxic lymphocytes; ELISPOT, enzyme linked immunospot; Cr, Chromium;</p></sec><sec><title>Competing Interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Author's contributions</title><p>All authors contributed to the ideas, discussion and preparation of this manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>NJW is a Peter Doherty fellow and CJPC is a PI of the Cancer Immunology Program funded by the NHMRC Australia</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waterhouse</surname><given-names>NJ</given-names></name><name><surname>Trapani</surname><given-names>JA</given-names></name></person-group><article-title>CTL: Caspases Terminate Life, but that's not the whole story</article-title><source>Tissue Antigens</source><year>2002</year><volume>59</volume><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">12074707</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0039.2002.590301.x</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waterhouse</surname><given-names>NJ</given-names></name><name><surname>Clarke</surname><given-names>CJ</given-names></name><name><surname>Sedelies</surname><given-names>KA</given-names></name><name><surname>Teng</surname><given-names>MW</given-names></name><name><surname>Trapani</surname><given-names>JA</given-names></name></person-group><article-title>Cytotoxic lymphocytes; instigators of dramatic target cell death</article-title><source>Biochem Pharmacol</source><year>2004</year><volume>68</volume><fpage>1033</fpage><lpage>1040</lpage><pub-id pub-id-type="pmid">15313398</pub-id><pub-id pub-id-type="doi">10.1016/j.bcp.2004.05.043</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roden</surname><given-names>MM</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Panelli</surname><given-names>MC</given-names></name><name><surname>Marincola</surname><given-names>FM</given-names></name></person-group><article-title>A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology</article-title><source>J Immunol Methods</source><year>1999</year><volume>226</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">10410969</pub-id><pub-id pub-id-type="doi">10.1016/S0022-1759(99)00039-3</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burrows</surname><given-names>SR</given-names></name><name><surname>Suhrbier</surname><given-names>A</given-names></name><name><surname>Khanna</surname><given-names>R</given-names></name><name><surname>Moss</surname><given-names>DJ</given-names></name></person-group><article-title>Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell-T-cell killing</article-title><source>Immunology</source><year>1992</year><volume>76</volume><fpage>174</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">1378424</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>JE</given-names></name><name><surname>Sherwood</surname><given-names>SW</given-names></name><name><surname>Clayberger</surname><given-names>C</given-names></name></person-group><article-title>A novel method for measuring CTL and NK cell-mediated cytotoxicity using annexin V and two-color flow cytometry</article-title><source>J Immunol Methods</source><year>1999</year><volume>224</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10357200</pub-id><pub-id pub-id-type="doi">10.1016/S0022-1759(98)00038-6</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jerome</surname><given-names>KR</given-names></name><name><surname>Sloan</surname><given-names>DD</given-names></name><name><surname>Aubert</surname><given-names>M</given-names></name></person-group><article-title>Measurement of CTL-induced cytotoxicity: the caspase 3 assay</article-title><source>Apoptosis</source><year>2003</year><volume>8</volume><fpage>563</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">14574062</pub-id><pub-id pub-id-type="doi">10.1023/A:1026123223387</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Chahroudi</surname><given-names>A</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Wernett</surname><given-names>ME</given-names></name><name><surname>Kaiser</surname><given-names>WJ</given-names></name><name><surname>Safrit</surname><given-names>JT</given-names></name><name><surname>Komoriya</surname><given-names>A</given-names></name><name><surname>Altman</surname><given-names>JD</given-names></name><name><surname>Packard</surname><given-names>BZ</given-names></name><name><surname>Feinberg</surname><given-names>MB</given-names></name></person-group><article-title>Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><fpage>185</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">11821904</pub-id><pub-id pub-id-type="doi">10.1038/nm0202-185</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okano</surname><given-names>M</given-names></name><name><surname>Purtilo</surname><given-names>DT</given-names></name></person-group><article-title>Simple assay for evaluation of Epstein-Barr virus specific cytotoxic T lymphocytes</article-title><source>J Immunol Methods</source><year>1995</year><volume>184</volume><fpage>149</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">7658018</pub-id><pub-id pub-id-type="doi">10.1016/0022-1759(95)00082-L</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rininsland</surname><given-names>FH</given-names></name><name><surname>Helms</surname><given-names>T</given-names></name><name><surname>Asaad</surname><given-names>RJ</given-names></name><name><surname>Boehm</surname><given-names>BO</given-names></name><name><surname>Tary-Lehmann</surname><given-names>M</given-names></name></person-group><article-title>Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity</article-title><source>J Immunol Methods</source><year>2000</year><volume>240</volume><fpage>143</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">10854609</pub-id><pub-id pub-id-type="doi">10.1016/S0022-1759(00)00191-5</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagury</surname><given-names>D</given-names></name></person-group><article-title>Direct analysis of individual killer T cells: susceptibility of target cells to lysis and secretion of hydrolytic enzymes by CTL</article-title><source>Adv Exp Med Biol</source><year>1982</year><volume>146</volume><fpage>149</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">7102458</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shafer-Weaver</surname><given-names>K</given-names></name><name><surname>Sayers</surname><given-names>T</given-names></name><name><surname>Strobl</surname><given-names>S</given-names></name><name><surname>Derby</surname><given-names>E</given-names></name><name><surname>Ulderich</surname><given-names>T</given-names></name><name><surname>Baseler</surname><given-names>M</given-names></name><name><surname>Malyguine</surname><given-names>A</given-names></name></person-group><article-title>The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity</article-title><source>J Transl Med</source><year>2003</year><volume>1</volume><fpage>14</fpage><pub-id pub-id-type="pmid">14697097</pub-id><pub-id pub-id-type="doi">10.1186/1479-5876-1-14</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trapani</surname><given-names>JA</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Functional significance of the perforin/granzyme cell death pathway</article-title><source>Nat Rev Immunol</source><year>2002</year><volume>2</volume><fpage>735</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">12360212</pub-id><pub-id pub-id-type="doi">10.1038/nri911</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wowk</surname><given-names>ME</given-names></name><name><surname>Trapani</surname><given-names>JA</given-names></name></person-group><article-title>Cytotoxic activity of the lymphocyte toxin granzyme B</article-title><source>Microbes Infect</source><year>2004</year><volume>6</volume><fpage>752</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">15207822</pub-id><pub-id pub-id-type="doi">10.1016/j.micinf.2004.03.008</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinkoski</surname><given-names>MJ</given-names></name><name><surname>Waterhouse</surname><given-names>NJ</given-names></name><name><surname>Heibein</surname><given-names>JA</given-names></name><name><surname>Wolf</surname><given-names>BB</given-names></name><name><surname>Kuwana</surname><given-names>T</given-names></name><name><surname>Goldstein</surname><given-names>JC</given-names></name><name><surname>Newmeyer</surname><given-names>DD</given-names></name><name><surname>Bleackley</surname><given-names>RC</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name></person-group><article-title>Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>12060</fpage><lpage>12067</lpage><pub-id pub-id-type="pmid">11278459</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M009038200</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimberly A Shafer-Weaver</surname><given-names>Thomas Sayers , Douglas B Kuhns , Susan L Strobl , Mark W Burkett , Michael Baseler and Anatoli Malyguine</given-names></name></person-group><article-title>Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay</article-title><source>Journal of Translational Medicine</source><year>2004</year><volume>2</volume><fpage>31</fpage><pub-id pub-id-type="pmid">15380049</pub-id><pub-id pub-id-type="doi">10.1186/1479-5876-2-31</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Thia</surname><given-names>KY</given-names></name><name><surname>Street</surname><given-names>SE</given-names></name><name><surname>MacGregor</surname><given-names>D</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name><name><surname>Trapani</surname><given-names>JA</given-names></name></person-group><article-title>Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma</article-title><source>J Exp Med</source><year>2000</year><volume>192</volume><fpage>755</fpage><lpage>760</lpage><pub-id pub-id-type="pmid">10974040</pub-id><pub-id pub-id-type="doi">10.1084/jem.192.5.755</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Thia</surname><given-names>KY</given-names></name><name><surname>Cretney</surname><given-names>E</given-names></name><name><surname>Kelly</surname><given-names>JM</given-names></name><name><surname>Snook</surname><given-names>MB</given-names></name><name><surname>Forbes</surname><given-names>CA</given-names></name><name><surname>Scalzo</surname><given-names>AA</given-names></name></person-group><article-title>Perforin is a major contributor to NK cell control of tumor metastasis</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>6658</fpage><lpage>6662</lpage><pub-id pub-id-type="pmid">10352283</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Street</surname><given-names>SE</given-names></name><name><surname>Trapani</surname><given-names>JA</given-names></name></person-group><article-title>Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>515</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">12847210</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bladergroen</surname><given-names>BA</given-names></name><name><surname>Meijer</surname><given-names>CJ</given-names></name><name><surname>ten Berge</surname><given-names>RL</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>Muris</surname><given-names>JJ</given-names></name><name><surname>Dukers</surname><given-names>DF</given-names></name><name><surname>Chott</surname><given-names>A</given-names></name><name><surname>Kazama</surname><given-names>Y</given-names></name><name><surname>Oudejans</surname><given-names>JJ</given-names></name><name><surname>van Berkum</surname><given-names>O</given-names></name><name><surname>Kummer</surname><given-names>JA</given-names></name></person-group><article-title>Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">11756176</pub-id><pub-id pub-id-type="doi">10.1182/blood.V99.1.232</pub-id></citation></ref></ref-list></back></article>



